
If Innovative Industrial Properties was on your watchlist rather than in your portfolio, the result may sting. Investors who held Innovative Industrial Properties over the past year are up 22.9%, including dividends. Back on 28 October 2025, analysts were building models around shrinking revenue, thinner margins and a higher future P/E multiple to justify fair value. The key question now is whether that cautious assumption about eroding cannabis real estate economics was ever the right anchor.
This theme extends beyond Innovative Industrial Properties. See which of 93 robotics and automation stocks may still merit a closer look.
The shares cost US$52.55 at the start of the period, and anyone weighing Innovative Industrial Properties then had to pick between two very different stories about cannabis real estate and where returns might come from.
On the cautious side, one bullish narrative still saw value, with a Fair Value of US$57 as the price implied by its model. This view assumed revenue that declined 3.7% a year and profit margins easing to 41.1%, together with a higher future P/E of 18.3x.
The bearish view argued that deeper damage was possible, using a Fair Value of US$45 and focusing on the risk that federal cannabis reform plus tenant distress could lift vacancies, force lease resets at lower rents, and leave long term revenues under pressure.
The clearest development was Innovative Industrial Properties lifting net income in Q2 2026 to US$39.5 million on US$63.3 million of revenue while net margin moved to 62.4%. That outcome challenged the earlier erosion story, which was built around shrinking profitability. Yet revenue in the quarter sat close to flat at about US$63 million, so the top line did not clearly break the cautious thesis.
The lesson is about which knob really matters. When a story hinges on pressured economics, track net margin first. Then see whether any improvement comes from healthier rent collection or one off items that may not stick.
Innovative Industrial Properties now trades at US$52.86. The selected Narrative places its Fair Value below that level and frames the gap around tenant credit quality, revenue pressure from cannabis assets, and the weight of the IQHQ exposure on future cash generation.
A buyer today effectively assumes tenant clean-up efforts, life sciences expansion, and current payouts all line up. The Narrative asks whether ongoing defaults and uncovered earnings power leave less room for disappointment than the share price implies.
"Current multiples and an 8x annualized NFFO valuation imply the share price already assumes that tenant remediation, dividend sustainability, and life sciences growth will succeed to a degree that leaves limited room for further disappointment."
That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for
What if your next investment idea came before the headlines? Go straight to the companies whose prices and our estimates still disagree. Three places to start, with the names waiting behind the link.
Those are three of them. See all 26 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com